Compare Stocks → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENASDAQ:IMNNNASDAQ:MNPRNASDAQ:PPBT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$4.32$11.07▼$35.71$11.99M1.183,849 shs3,700 shsIMNNImunon$1.33+1.5%$1.20$0.48▼$2.00$12.50M2.04175,159 shs54,612 shsMNPRMonopar Therapeutics$0.73+10.7%$0.76$0.27▼$1.75$11.52M1.17144,858 shs129,520 shsPPBTPurple Biotech$0.53-1.9%$0.65$0.30▼$2.08$13.65M1.01255,202 shs103,438 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%0.00%+4,274.38%+3,143.24%IMNNImunon+1.53%-7.64%-4.32%+141.82%+5.56%MNPRMonopar Therapeutics+11.71%+10.48%+13.27%+99.78%-24.25%PPBTPurple Biotech-2.03%+8.16%-24.97%-27.40%-72.75%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMNNImunon1.3681 of 5 stars3.53.00.00.00.00.01.3MNPRMonopar Therapeutics2.4459 of 5 stars3.55.00.00.00.61.70.6PPBTPurple Biotech1.3268 of 5 stars3.53.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AIMNNImunon3.00Buy$13.00877.44% UpsideMNPRMonopar Therapeutics3.00Buy$2.00175.03% UpsidePPBTPurple Biotech3.00Buy$9.001,598.11% UpsideCurrent Analyst RatingsLatest AGE, PPBT, IMNN, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/26/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.004/1/2024IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/13/2024IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00IMNNImunon$500K25.00N/AN/A$1.42 per share0.94MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)IMNNImunon-$19.51M-$2.18N/AN/AN/AN/A-98.04%-66.49%5/9/2024 (Estimated)MNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)PPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)Latest AGE, PPBT, IMNN, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023IMNNImunon-$0.59-$0.52+$0.07-$0.52N/AN/A3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/A3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36IMNNImunonN/A2.472.47MNPRMonopar TherapeuticsN/A4.174.17PPBTPurple BiotechN/A2.202.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%IMNNImunon4.47%MNPRMonopar Therapeutics1.83%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%IMNNImunon3.84%MNPRMonopar Therapeutics41.60%PPBTPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableIMNNImunon339.40 million9.04 millionNot OptionableMNPRMonopar Therapeutics917.45 million10.19 millionNot OptionablePPBTPurple Biotech2025.24 million24.49 millionOptionableAGE, PPBT, IMNN, and MNPR HeadlinesSourceHeadlinePurple Biotech (NASDAQ:PPBT) Earns "Buy" Rating from HC Wainwrightamericanbankingnews.com - April 28 at 4:14 AMPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meetingglobenewswire.com - April 25 at 7:00 AMPurple Biotech (NASDAQ:PPBT) Trading Up 8.1%americanbankingnews.com - April 24 at 2:18 AMPurple Biotech Ltd (PPBT)investing.com - April 17 at 11:15 PMPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024finance.yahoo.com - March 28 at 11:13 AMPurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyfinanznachrichten.de - March 14 at 12:40 PMPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyglobenewswire.com - March 14 at 7:30 AMHere's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisherzacks.com - March 13 at 10:56 AMPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023investorplace.com - March 5 at 11:52 PMPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 5 at 1:22 PMPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 5 at 7:55 AMPurple Biotech ADR (PPBT) Earnings Dates & Reportsinvesting.com - March 3 at 6:09 PMBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatmentmarkets.businessinsider.com - February 27 at 10:57 PMPurple Biotech Ltd ADRmorningstar.com - February 27 at 5:56 PMPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024globenewswire.com - February 27 at 7:00 AMPurple Biotech Ltd. ADRwsj.com - February 22 at 2:20 PMPurple Biotech Ltd ADR PPBTmorningstar.com - February 15 at 12:30 AMPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trialfinance.yahoo.com - February 13 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)markets.businessinsider.com - February 1 at 5:47 PMPurple Biotech stock climbs 9% on Phase 2 study updatemsn.com - February 1 at 12:47 PMPurple Biotech Reaches Recommended Phase 2 Dose for NT219finance.yahoo.com - February 1 at 7:47 AMPurple Biotech Appoints Dr. Yael Margolin to its Board of Directorsfinance.yahoo.com - December 20 at 9:18 AMPurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinanznachrichten.de - December 14 at 10:30 AMPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinance.yahoo.com - December 14 at 10:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeHasbro’s Management Made All the Right Calls This QuarterApril 25, 2024 11:16 AMView Hasbro’s Management Made All the Right Calls This QuarterYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyWestern Digital Slips Despite EPS Beat and Raise - Buy Time? April 29, 2024 7:45 AMView Western Digital Slips Despite EPS Beat and Raise - Buy Time? Vital Farms Rides the Pasture-Raised Egg Trend to the Bank April 15, 2024 7:40 AMView Vital Farms Rides the Pasture-Raised Egg Trend to the Bank All Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.ImunonNASDAQ:IMNNImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.